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ABSTRACT
Chemotherapy plays a crucial role in treatment of colorectal cancer (CRC). Its 
effectiveness, however, is often hampered by toxicity-limiting therapeutic effect and drug 
resistance. Probiotics are thought to be able to prevent CRC through changing of colonic 
microbiota. This study examined the anticancer of Malaysian LAB and unravel the 
underlying mechanisms against CRC. Twelve LAB isolated from locally fermented food 
were screened for anticancer against HCT 116, HT-29 and DLD-1 using MTT assay. 
CRC cells treated with either LAB strain eliciting the most potent anticancer or 
Lactobacillus casei strain Shirota (reference strain; LABPC) were subjected to detection 
of apoptosis by AO/PI staining. The mode of cell death was confirmed by annexin V- 
FITC/PI. The in vitro findings were validated using a HCT 116 tumour xenograft model 
(n=6/group). Oral administration (109cfu/ml) of LAB 12 and LABPC, either in freeze 
dried form (FD) or fermented in soymilk (SM), was performed daily before and after 
tumour inoculation. Tumours were then excised and homogenized for nitric oxide (NO) 
production, pro-inflammatory cytokine levels (IL-la, IL-8 and VEGF), antioxidant 
activity (SOD, CAT and GSH) and caspase-3 activation. The metabolic profiling of 
serum was also performed using LC/MS Q-TOF and differential expression of the 
metabolites was established by clustering analysis. Anticancer screening revealed that 
whilst both HT-29 and DLD-1 remained viable in the presence of all tested LAB, HCT 
116 were particularly sensitive to treatment with Lactobacillus plantarum (LAB 12) 
(IC5o=57.70% ± 39.69) and LABPC (IC50=44.87% ± 18.63) fermented in RPMI. 
Confocal microscopy of AO/PI stained LAB 12- and LABPC-treated HCT 116 confirmed 
the presence of apoptotic bodies, chromatin condensation and fragmentation as well as 
membrane blebbing. Subsequent detection of apoptosis found increased percentage of 
HCT 116 in early and late apoptotic (indicative of apoptosis) stages following 24, 48 and
72 h treatment with LAB 12 (4.58-46.46%) and LABPC (6.72-51.45%), respectively 
when compared to untreated HCT 116. In vivo study showed reduction of tumour volume 
(41%-65%) and weight (22%-46%) in LAB 12- and LABPC-treated mice. Tumour 
homogenates of LAB 12- and LABPC-treated mice were presented with down-regulation 
of NO (57%-77%) and pro-inflammatory cytokine [EL-la (34%-71%), IL-8 (15%-67%) 
and VEGF (18%-64%)] as well as up-regulation of caspase-3 (16%-68%) and antioxidant 
enzymes [SOD (20%-37%), CAT (37%-46%) and GSH (43%-71%)] levels. Metabolic 
profiling of serum from LAB 12- and LABPC-treated mice identified significant (p<0.05) 
up-regulation of nine metabolites associated with antitumour activity and they include 
eicosapentaenoic acid (5.92-12.14), palmitic acid (8.93-9.12), undecanoic acid (1.46- 
5.86), docosapentaenoic acid (3.89-12.64), oleamide (12.52-13.59), dihydroxyvitamin D3 
(5.71-6.14), dihydrosphiongosine (13.96-14.09), phytosphingosine (14.99-15.61) and C16 
sphinganine (15.99-16.91). The present study reports for the first time that the anticancer 
effect of LAB 12 and LABPC was mediated through the induction of apoptosis. The 
apoptotic effect was associated with up-regulation of antioxidant activities and anticancer 
metabolites levels as well as down-regulation of nitric oxide and pro-inflammatory 
cytokines. These findings suggest the potential use of Malaysian LAB for prevention of 
CRC.
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CHAPTER ONE 
INTRODUCTION
Colon cancer is one of the most common cancers worldwide, particularly amongst 
developed countries in the west (Wu et al., 2012). In Asian population, which includes 
Malaysians, there is a rapid increase in the incidence of colon cancer (Natrah, Ezat, Syed, 
Rizal & Saperi, 2012). The risk of developing this malignancy is greatly influenced by 
age, genetic, environment and change in dietary and lifestyle factors (Yamall, Crouch & 
Lewis, 2013). It is estimated that dietary factors such as high intake of red and processed 
meat as well as low levels of fiber contributed to approximately one half of all colon 
cancer cases (Wu et al., 2012; Yamall, Crouch & Lewis, 2013).
The current treatment regimens for colon cancer are extensive, and they include 
surgery and chemotherapy, both of which are highly dependent on tumour stage. When 
colon cancer is detected during the early stage, surgery is the preferred option. However, 
the success of this strategy is limited by development of scar tissue in the abdomen that 
can cause organ or tissue to stick together and block the bowel [American Cancer Society 
(ACS), 2014]. Metastatic cancers are usually treated by chemotherapy. In colon cancer, 
conventional chemotherapy is not as effective when compared to other cancers because 
drugs do not reach the target site in effective concentration (Mishra, Ramasamy & 
Majeed, 2012). The non-selectivity of anticancer agents causes high level of side effects 
and thus affects the patients’ quality of life. Therefore, it is of great importance to 
discover and develop novel agents with low side effects, improved safety and maximum 
efficacy as well as the ability to overcome drug resistance (Yang et al., 2012).
There is evidence indicating that ingestion of probiotics is able to diminish the 
risk of cancer and inhibit tumour growth (Choi et al., 2006; Kim, Oh, Yun & Kim, 2010). 
Probiotics are living microorganisms, which can confer benefit on the host when 
consumed in sufficient amount (FAO/WHO, 2002). The most common probiotics include 
the lactic acid bacteria (LAB), with most attention focused on the members of genera 
Lactobacillus and Bifidobacterium (Florence et al., 2012). These organisms have been 
widely reported to exert many beneficial effects in that they stimulate the growth of 
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